ATE334119T1 - Geldanamycinderivate zur krebsbehandlung - Google Patents

Geldanamycinderivate zur krebsbehandlung

Info

Publication number
ATE334119T1
ATE334119T1 AT02757908T AT02757908T ATE334119T1 AT E334119 T1 ATE334119 T1 AT E334119T1 AT 02757908 T AT02757908 T AT 02757908T AT 02757908 T AT02757908 T AT 02757908T AT E334119 T1 ATE334119 T1 AT E334119T1
Authority
AT
Austria
Prior art keywords
anamycin
money
derivatives
cancer treatment
host
Prior art date
Application number
AT02757908T
Other languages
English (en)
Inventor
Kenneth M Snader
B Rao Vishnuvajjala
Melinda G Hollingshead
Edward A Sausville
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE334119T1 publication Critical patent/ATE334119T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT02757908T 2001-03-30 2002-03-28 Geldanamycinderivate zur krebsbehandlung ATE334119T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28007801P 2001-03-30 2001-03-30

Publications (1)

Publication Number Publication Date
ATE334119T1 true ATE334119T1 (de) 2006-08-15

Family

ID=23071560

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02757908T ATE334119T1 (de) 2001-03-30 2002-03-28 Geldanamycinderivate zur krebsbehandlung

Country Status (19)

Country Link
US (1) US6890917B2 (de)
EP (1) EP1373215B1 (de)
JP (1) JP4213472B2 (de)
KR (1) KR100831133B1 (de)
CN (1) CN1262542C (de)
AT (1) ATE334119T1 (de)
AU (1) AU2002307020B2 (de)
CA (1) CA2430692C (de)
CY (1) CY1107484T1 (de)
DE (1) DE60213386T2 (de)
DK (1) DK1373215T3 (de)
ES (1) ES2268068T3 (de)
IL (2) IL156122A0 (de)
MX (1) MXPA03007856A (de)
NZ (1) NZ526133A (de)
PT (1) PT1373215E (de)
SI (1) SI21369A (de)
WO (1) WO2002079167A1 (de)
ZA (1) ZA200304178B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
WO2005009345A2 (en) 2003-06-13 2005-02-03 Kosan Biosciences, Inc. 2-desmethyl ansamycin compounds
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
EP1682514A4 (de) * 2003-11-12 2008-07-16 Kosan Biosciences Inc 11- o-methylgeldanamycinverbindungen
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
WO2005063714A1 (en) 2003-12-23 2005-07-14 Infinity Pharmaceuticals, Inc Analogs of benzoquinone-containing ansamycins for the treatment of cancer
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US7259156B2 (en) 2004-05-20 2007-08-21 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
EP1863769A4 (de) * 2005-03-11 2009-03-18 Univ Colorado Hsp90-inhibitoren, verfahren zu deren herstellung und deren anwendungen
JP2008539273A (ja) * 2005-04-29 2008-11-13 コーザン バイオサイエンシス インコーポレイテッド １７−ａａｇ又は１７−ａｇ又はどちらかのプロドラッグをプロテアソーム阻害剤と組み合わせて使用する多発性骨髄腫の治療方法
US20100279994A1 (en) * 2005-06-21 2010-11-04 Inifinity Discovery, Inc. Ansamycin Formulations and Methods of Use Thereof
WO2007059116A2 (en) * 2005-11-14 2007-05-24 Abraxis Bioscience, Inc. Geldanamycin derivatives and pharmaceutical compositions thereof
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
WO2007098229A2 (en) * 2006-02-21 2007-08-30 Michigan State University Geldanamycin derivatives and method of use thereof
CN100519536C (zh) * 2006-03-21 2009-07-29 中国医学科学院医药生物技术研究所 一组连有核苷碱基的格尔德霉素衍生物
US20070293451A1 (en) * 2006-05-02 2007-12-20 University Of Pittsburgh Regulation ao ApoB by Hsp110 proteins and related compositions and methods
KR100796637B1 (ko) * 2006-09-29 2008-01-22 한국생명공학연구원 젤다나마이신 유도체, 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 및치료제
CN100500668C (zh) * 2006-12-19 2009-06-17 中国人民解放军军事医学科学院毒物药物研究所 格尔德霉素衍生物及其制备方法和制备药物的用途
US7855192B2 (en) * 2007-01-26 2010-12-21 Kosan Biosciences, Inc. Macrolactams by engineered biosynthesis
WO2008118601A2 (en) * 2007-02-27 2008-10-02 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Radiolabeled affibody molecules
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
CN101677991A (zh) * 2007-04-12 2010-03-24 英菲尼蒂发现公司 氢醌安莎霉素制剂
WO2009026548A1 (en) 2007-08-23 2009-02-26 The Regents Of The University Of Colorado Hsp90 inhibitors with modified toxicity
WO2009036092A2 (en) 2007-09-10 2009-03-19 University Of Massachusetts Mitochondria-targeted anti-tumor agents
US20090186039A1 (en) * 2008-01-18 2009-07-23 Jang Sung-Key Novel use of grp 94 in virus infection
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
KR20110090925A (ko) 2008-10-15 2011-08-10 인피니티 파마슈티컬스, 인코포레이티드 안사마이신 하이드로퀴논 조성물
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
JPWO2011040421A1 (ja) 2009-09-29 2013-02-28 武田薬品工業株式会社 スクリーニング方法
CN102030764B (zh) * 2010-11-12 2012-07-04 中国医学科学院医药生物技术研究所 4，5双氢噻嗪酮格尔德霉素及其制备方法
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
CN102603635B (zh) * 2011-01-21 2016-08-03 杭州华东医药集团生物工程研究所有限公司 格尔德霉素衍生物及其制备方法和用途
US8921533B2 (en) 2011-07-25 2014-12-30 Chromatin Technologies Glycosylated valproic acid analogs and uses thereof
US9603829B2 (en) 2011-11-14 2017-03-28 The Regents Of The University Of Colorado, A Body Corporate HSP90 inhibitors with modified toxicity
CN102552150B (zh) * 2012-03-02 2013-10-30 首都医科大学 一种格尔德霉素脂质体的制备及应用
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55111469A (en) 1979-02-19 1980-08-28 Kaken Pharmaceut Co Ltd Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
JPS55111470A (en) 1979-02-19 1980-08-28 Kaken Pharmaceut Co Ltd Geldanamycin derivative, its preparation, antitumor drug comprising it as active ingredient
JPS55111419A (en) 1979-02-20 1980-08-28 Kaken Pharmaceut Co Ltd Antitumorigenic agent
CA2166320A1 (en) * 1993-06-29 1995-01-12 Randall James Gallaschun Ansamycin derivatives as antioncogene and anticancer agents
JPH09502614A (ja) * 1993-09-14 1997-03-18 メルク エンド カンパニー インコーポレーテッド 新規ヒト蛋白質チロシンホスファターゼをコードするｃＤＮＡ
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
WO1996034525A1 (en) * 1995-05-02 1996-11-07 The Regents Of The University Of California Inducement of thermotolerance with benzoquinonoid ansamycins
US5958892A (en) * 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US5948814A (en) * 1997-02-20 1999-09-07 The Curators Of The University Of Missouri Genistein for the treatment of cystic fibrosis
US5952175A (en) * 1997-10-09 1999-09-14 Incyte Pharmaceuticals, Inc. DNA encoding a human progesterone receptor complex p23-like protein
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration

Also Published As

Publication number Publication date
CA2430692C (en) 2011-05-31
IL156122A (en) 2010-11-30
CN1262542C (zh) 2006-07-05
NZ526133A (en) 2005-08-26
CA2430692A1 (en) 2002-10-10
MXPA03007856A (es) 2003-12-04
KR20040023581A (ko) 2004-03-18
IL156122A0 (en) 2003-12-23
PT1373215E (pt) 2006-12-29
DE60213386D1 (de) 2006-09-07
SI21369A (sl) 2004-06-30
DK1373215T3 (da) 2006-11-13
US20040053909A1 (en) 2004-03-18
ES2268068T3 (es) 2007-03-16
DE60213386T2 (de) 2006-11-23
EP1373215B1 (de) 2006-07-26
JP4213472B2 (ja) 2009-01-21
CY1107484T1 (el) 2013-03-13
JP2004519514A (ja) 2004-07-02
AU2002307020B2 (en) 2007-06-28
ZA200304178B (en) 2004-02-17
KR100831133B1 (ko) 2008-05-20
WO2002079167A1 (en) 2002-10-10
CN1484639A (zh) 2004-03-24
EP1373215A1 (de) 2004-01-02
US6890917B2 (en) 2005-05-10

Similar Documents

Publication Publication Date Title
ATE334119T1 (de) Geldanamycinderivate zur krebsbehandlung
AU2003253877A1 (en) Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs
WO2005000213A3 (en) Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
NO20014842L (no) Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft
WO2002005791A3 (en) Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
WO2005000212A8 (en) Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors
MXPA03003632A (es) Metodo para tratamiento de tumores usando terapia de combinacion.
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
WO2004110151A8 (en) Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
HK1069327A1 (en) Use of ginkgo biloba extracts for preparing a medicine for treating sarcopenia
EP1262197A3 (de) Kombinationstherapie zur Behandlung von Schlafstörungen, Schlaflosigkeit inbegriffen
GB0020504D0 (en) Therapeutic method
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
MXPA01007031A (es) Metodo para tratar enfermedades acrdiacas cronicas.
IL153426A0 (en) Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
WO2003079748A3 (en) Potentiation of cancer therapies by znf217 inhibition
BR0308976A (pt) Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia
WO2004035030A3 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain
WO2003072737A3 (en) Biological inhibitions induced by contact inhibitory factor
TNSN03022A1 (en) Method for treatment of inflammation
UA36251A (uk) Спосіб комплексної терапії простої шизофренії
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1373215

Country of ref document: EP